Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 8/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.34 |
| ▸ | FGF1 | P05230 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321920 | 0.88 | F10 (0.40) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL13130299 | 0.84 | LGALS3 (0.42) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL13130297 | 0.80 | LGALS3 (0.38) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL18022304 | 0.77 | CD69 (0.47) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL14444723 | 0.77 | LMNA (0.34) | LGALS3LGALS7; LGALS7BLGALS1LGALS9ALDH1A1 | |
| SCHEMBL23490992 | 0.74 | CD69 (0.48) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 | |
| SCHEMBL13321919 | 0.74 | BDNF (0.47) | CD69LGALS3LGALS7; LGALS7BLGALS1FGF1 | |
| SCHEMBL13895616 | 0.73 | CD69 (0.49) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL23491004 | 0.73 | CD69 (0.49) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL10014366 | 0.73 | LGALS3 (0.51) | CD69LGALS3LGALS7; LGALS7BLGALS1LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394781-B2 | Disaccharides for the treatment of tendons, ligaments, and bones | BIOIBERICA, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| US-20100129331-A1 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES | BIOIBERICA, S.A. (ES) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129331-A1 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES | IGFBP1, FGF1, IGFBP2 | CD69 593/4885LGALS3 48/4885LGALS7; LGALS7B 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.